Eli Lilly (NEO:LLY)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Eli Lilly Charts. Click Here for more Eli Lilly Charts.](/p.php?pid=staticchart&s=NEO%5ELLY&p=8&t=15)
Cellular Genomics Establishes Research Collaboration With Lilly
BRANFORD, Conn., Dec. 17 /PRNewswire/ -- Cellular Genomics Inc. (CGI), a
chemical genetics based biopharmaceutical company, today announced that it has
entered into a research collaboration with Eli Lilly and Company, under which
CGI will apply its chemical genetics Analog Sensitive Kinase Allele (ASKA)
technology to the study of kinase drug targets selected by Lilly.
"We are extremely pleased that Lilly has chosen to collaborate with CGI to
further enhance their kinase drug discovery programs," said Dr. Louis Matis,
President and Chief Executive Officer of CGI. "This marks the fifth
collaboration we have established with a major pharmaceutical or biotechnology
company based on our patented chemical genetics technologies, demonstrating
their value and utility."
CGI's cutting-edge chemical genetics approach is based on the discovery of
Analog Sensitive Kinase Alleles (ASKAs). ASKAs are genetically modified kinases
that retain all the functions of normal kinases, but can be potently inhibited
with exquisite selectivity and specificity by a specially designed proprietary
small molecule analog inhibitor. This enables drug discovery scientists to
quickly understand the pharmacological consequences of specific kinase
inhibition and, therefore, the likely therapeutic benefit of inhibiting the
normal kinase target with a small molecule drug. CGI holds the exclusive
worldwide license to this broadly enabling chemical genetics technology, which
has powerful applications to multiple facets of the drug discovery process.
These include: cell pathway based target identification; rigorous,
pharmaceutically relevant in vivo target validation; proprietary high-content
cell-based drug screens; and in vivo systems that provide key therapeutic index
and drug safety information to guide the selection of optimal drug candidates
for clinical development.
Under the terms of the agreement, CGI will use its ASKA technology to generate
modified kinases for Lilly. CGI's P-inhibitor technology will be utilized to
design and validate unique cell-based assays specific for the kinases of
interest to Lilly. These assays have the potential to accelerate Lilly's lead
identification efforts against the kinase targets.
About CGI:
Cellular Genomics Inc. (CGI) is a privately held chemical genetics-based
biopharmaceutical company that is pioneering a unique, highly integrated
chemical genetics platform to discover and develop kinase and other signal
transduction inhibitors for multiple clinical indications. CGI has established
state-of-the art small molecule drug discovery capabilities, including
proprietary chemical libraries generated through the company's High-throughput
Accelerated Lead Optimization (HALO) platform. CGI has generated potent,
selective lead candidates in three drug discovery and development programs in
autoimmune and inflammatory disease, cancer, and angiogenesis that are advancing
rapidly toward the clinic. CGI's proprietary chemical genetics technologies
have broad applications across all phases of drug discovery, which the company
is leveraging both to advance its own internal drug development programs as well
as to establish partnerships with pharmaceutical and biotechnology companies.
The Company has established research collaborations with several pharmaceutical
and biotechnology companies. Please visit http://www.cellulargenomics.com/ for
additional information.
DATASOURCE: Cellular Genomics Inc.
CONTACT: Louis A. Matis, M.D., President and CEO of Cellular Genomics,
Inc., +1-203-315-1222; Rhonda Chiger (Investors), +1-917-322-2569, or Pete
Holmberg (Media), +1-917-322-2164, both of Rx Communications Group for
Cellular Genomics, Inc.
Web site: http://www.cellulargenomics.com/